Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

GE HealthCare announced that the NCCN Guidelines for Clinical Oncology now recommend FES PET for systemic staging in patients ...

PET/CT is a useful tool to map out the possible sites where the cancer first originated. PET/CT is a form of hybrid imaging that combines computed tomography (CT), an anatomical imaging ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

This growth is fueled by the rising prevalence of chronic diseases, increasing demand for non-invasive diagnostic tools, and the integrati ...

Dr Kunjahari Medhi, is a Medical & Haemato oncologist, Medanta hospital, Gurgaon, 5 star rated in his Google Profile Review. He comes to me as an amiable, family doctor who puts patients at ease ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...

Intermountain Health Park City Hospital CEO Lori Weston shares details on the $40 million investment to add a 10,000 square ...

The lung cancer diagnostics market encompasses tools, techniques, and services for detecting lung cancer, including imaging, ...